Xilio Therapeutics

IPO

Tumor-selective Immunotherapy

Waltham, United States · Founded 2016 · $225.5M raised

Founded
2016
Business Model
B2B
Total Funding
$225.5M
Last Round
$95.0M Series CFeb 2021
Rounds
3

About

Xilio is a clinical-stage biotechnology company developing masked immuno-oncology therapies for people living with cancer. Its biology and protein-engineering approach creates biologics that remain inactive until they reach the tumor microenvironment, where tumor-specific proteases activate them. The company is advancing preclinical and clinical programs for masked multi-specific therapies.

Summary

Xilio Therapeutics is a Biotech company based in Waltham, United States, founded in 2016. It has raised $225.5M in total across 3 rounds, most recently a $95.0M Series C round in Feb 2021. Investors include SV Health Investors, Coastlands Capital and Frazier Life Sciences.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOOct 2021
$117.6M

Sign up to see all 4 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Xilio Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/xilio-therapeutics"><img src="https://indexed.vc/api/badge/company/xilio-therapeutics" alt="Xilio Therapeutics on Indexed.vc" width="260" height="76" /></a>